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Store-operated calcium (SOC) channels are vital
for activation of the immune cells, and mutations in
the channel result in severe combined immunode-
ficiency in human patients. In lymphocytes, SOC
entry is mediated by the Orai1 channel, which is acti-
vatedbydirect bindingofSTIM1.Herewedescribean
alternative approach for identifying inhibitors of SOC
entry usingminimal functional domains of STIM1 and
Orai1 to screen a small-molecule microarray. This
screen identified AnCoA4, which inhibits SOC entry
at submicromolar concentrations and blocks T cell
activation in vitro and in vivo. Biophysical studies
revealed that AnCoA4 binds to the C terminus of
Orai1, directly inhibiting calcium influx through the
channel and also reducing binding of STIM1. An-
CoA4, unlike other reported SOC inhibitors, is a
molecule with a known binding site and mechanism
of action. These studies also provide proof of princi-
ple for an approach to ion channel drug discovery.
INTRODUCTION
Calcium is the most abundant second messenger in cell sig-
naling, and its tight regulation is necessary for a broad variety
of cellular events, including proliferation, migration, and gene
expression. Store-operated calcium (SOC) channels are the
major source of calcium influx in many nonexcitable cells,
including T lymphocytes and mast cells. SOC entry is activated
by inositol-phosphate-coupled production of phosphatidylinosi-
tol 4, 5 bisphosphate (inositol 1,4,5-trisphosphate [IP3]), which
binds to IP3 receptors in the endoplasmic reticulum (ER) and
causes release of calcium from ER calcium stores. Depletion
of ER calcium stores triggers calcium influx across the cell mem-1278 Chemistry & Biology 21, 1278–1292, October 23, 2014 ª2014 Ebrane, which is essential for activating biochemical cascades in
immune cells and leads to changes in gene expression, cytokine
production, and cell proliferation.
SOC entry is mediated by calcium-release-activated calcium
(CRAC) channels, which are composed of the proteins STIM
and Orai (Hoth and Penner, 1992; Lewis and Cahalan, 1989).
STIM1 and its close homolog STIM2 are single-transmem-
brane-domain proteins that reside mainly in the membrane of
the ER and form the ER calcium sensor of the channel. Orai1
1, 2, and 3 are transmembrane-domain proteins that are local-
ized in the plasma membrane and form the pore of the channel
(Feske et al., 2006; Liou et al., 2005; Roos et al., 2005; Vig
et al., 2006). Depletion of calcium from the ER leads to a confor-
mational change in an EF-hand calcium-binding domain of
STIM, causing STIM aggregation into puncta and exposing an
Orai1-binding domain called the CRAC-activating domain
(CAD) (Park et al., 2009). CAD binds to Orai1, clustering Orai1
into puncta and opening the channel, thus leading to calcium
influx into the cell from the extracellular environment.
Although STIM and Orai are expressed in a variety of tissues,
they are particularly important in the function of immune cells.
Orai1 and STIM1 are the major source of calcium entry in human
immune cells and are required for immune cell activation (Gwack
et al., 2007; McCarl et al., 2010; Oh-Hora et al., 2008). Homozy-
gous mutations in human Orai1 and STIM1 cause severe com-
bined immunodeficiency (SCID) syndrome in human patients
(Feske et al., 2006; McCarl et al., 2009). Loss of function of
Orai1 and STIM1 in mouse models causes defects in Th1, Th2,
Th17, B cell, and platelet activation (Feske, 2007; Feske, 2010;
Shaw and Feske, 2012).
Because of their central importance in regulation of the im-
mune system, the SOC channels have been the target of several
drug discovery efforts. The main intracellular target of calcium
influx through SOC channels is the calcium-regulated phospha-
tase calcineurin. Calcineurin dephosphorylates the nuclear fac-
tor of activated T cells (NFAT) family of transcription factors
that regulate pathways of gene expression required for the
production of cytokines, such as IL2, IL3, and TNFa, that affectlsevier Ltd All rights reserved
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tant clinical target for immune modulation, and calcineurin inhib-
itors cyclosporin A (CsA) and tacrolimus are the most widely
used immunosuppressant agents in patients.
Clinically approved immunosuppressant agents such as CsA
and steroids have a number of potentially serious side effects,
including hypertension, nephrotoxicity, and liver damage (Burd-
mann et al., 2003; Hoorn et al., 2011). It has been proposed that
inhibitors of Orai1 might have fewer side effects, as Orai1 chan-
nels play amuchmore specific andwell-defined role inSOC influx
than cyclophilin and FKBP12, which are the targets of CsA and
tacrolimus. This hypothesis is supported by the observation
that patients with Orai1 mutations have SCID, mild muscular
myotonia, and ectodermal dysplasia but are largely free of other
disorders (Feske, 2009; Shaw and Feske, 2012). Several groups
have therefore begun to look for blockers of Orai1 channels,
and relatively nonspecific blockers have been described,
including2APB, a repurposed inositol trisphosphate receptors in-
hibitor, andYM-58483 (Diver et al., 2001;Takezawaet al., 2006). A
recent paper from a group at Hoffmann-La Roche reported the
discovery of RO2959, a relatively potent CRAC channel inhibitor
with half maximal inhibitory concentration (IC50) values of about
200 nM, depending on the assay (Chen et al., 2013). To achieve
these IC50 values, however, thismolecule had to be preincubated
with cells for 30 to 60min, suggesting that itmay act onOrai1 indi-
rectly. This compound and most of the other Orai1 inhibitors that
have been published were identified using cell-based screening
assays. One disadvantage of this approach is that the molecular
mechanism by which it blocks Orai1 is not understood. Specif-
ically, it is not known whether this compound binds directly to
Orai1 or inhibits the channel by binding to a different protein.
This lack of understanding of the binding site and mechanism
makes it difficult to improve the specificity or pharmacodynamics
of the compound using structure function studies.
Here, we report an alternative approach for identifying inhibi-
tors of CRAC channel function that takes advantage of existing
knowledge of the minimal functional domains (MFD) of ion chan-
nel proteins.We generated in vitro purified peptides encompass-
ing Orai1 and STIM1 domains that are important for the gating
of the SOC ion channels. Using these domains, we rapidly and
inexpensively screened a small-molecule microarray (SMM)
and identified several blockers of Orai1. We characterized the
mechanism and showed that one of these blockers, AnCoA4,
binds to and inhibit the Orai1 channel. We then demonstrated
that AnCoA4 is an effective immunosuppressant in vitro and
in vivo. This platform could dramatically increase the speed of
screening efforts and efficiency of lead compound optimization
for various ion channels.
RESULTS
SMM Screen for Inhibitors of SOC
Since the discovery of STIM1 andOrai1, important functional do-
mains of these proteins have been identified by various groups.
The N terminus of Orai1 binds directly to STIM1, calmodulin,
and SPCA2 and plays an important role in channel gating and
inactivation (Feng et al., 2010; Mullins et al., 2009; Park et al.,
2009). The C terminus of Orai1 also binds to STIM1 and is essen-
tial for gating of the channel aswell for aggregation into clusters atChemistry & Biology 21, 1278–1ER-plasma membrane junctions (Frischauf et al., 2009; Muik
et al., 2008). Structure function analysis of STIM proteins has
also revealed several important functional domains, including
the EF-hand and SAM domains in the lumen that are important
for calcium store-dependent conformational changes and the
CAD, a 107 amino acid fragment of the STIM1 molecule that by
itself can activate Orai1 channels by directly binding to its N and
C termini (Park et al., 2009). Discovery of these MFDs of STIM1
andOrai1 and understanding their mechanism of action provides
an opportunity to identify small molecules that bind to these do-
mains and can modify different aspects of channel function.
SMMs are collections of organic molecules arrayed on modi-
fied glass slides (Seiler et al., 2008; Vegas et al., 2008). They
provide a fast and inexpensive method for identifying small
molecules that bind to specific proteins and have been used
to obtain inhibitors of tyrosinases, g-secretase, and cathepsins,
among others (Shi et al., 2009, 2011). To identify small mole-
cules that bind to the MFDs of Orai1 and STIM1, we generated
glutathione S-transferase (GST) fusions of the CAD of STIM1
and MFDs in the N terminus, 2-3 loop, and C terminus of
Orai1 (Figures S1A and S1B available online). We then incu-
bated SMMs containing 12,000 compounds with the GST
fusion proteins, and fluorescent anti-GST antibodies were
used to detect binding of the MFDs to specific compounds im-
mobilized on the SMMs (Figure 1A). The screen was carried out
in triplicate, and a composite Z score was calculated for the
binding of each small molecule (Figure 1B). Although the
outcome of this screen using the GST-CAD was not robust
enough, resulting in compounds with low composite Z scores,
we identified 120 compounds that bound to the Orai1 peptides
with composite Z score values of three SDs from the mean
(Figure 1C; Figures S1C and S1D). Fifty-one of these were
commercially available and were prioritized for evaluation in
secondary functional assays.
To determine whether these compounds affected the func-
tion of Orai1 and STIM1 in intact cells, we used a NFAT reporter
gene assay in human embryonic kidney 293T (HEK293T) cells.
Activation of STIM1 and Orai1 results in calcium influx and
subsequent dephosphorylation and activation of the NFAT tran-
scription factor. We first treated cells with each of the 51 com-
pounds at a single dose (50 mM) for 6 hr in the presence of 1 mM
thapsigargin (TG) to activate SOC entry and measured NFAT-
luciferase expression (Figure 1D). We used Renilla luciferase
as an internal control to monitor the viability of cells (Figure 1E).
To confirm that AnCoA4 does not cause gross toxicity, we
tested cell viability in rat basophilic leukemia (RBL) cells using
a 1-N-methyl-5-thiotetrazole (MTT) assay (Figure S1E). Four
of the 51 compounds suppressed the activation of the NFAT-
luciferase reporter gene without affecting cell viability, sug-
gesting that they inhibit Orai1 channel activation. We next
generated dose-response curves for these four compounds
and found that AnCoA5 (compound 25) and AnCoG4 (com-
pound 23) inhibited NFAT-luciferase only at concentrations
greater than 10 mM (Figures 1F and 1G). In contrast, AnCoF6
(compound 38) and AnCoA4 (compound 17), which differ by
only a methoxy group, inhibited NFAT-luciferase with much
higher potency (Figures 1H and 1I). AnCoA4 showed the high-
est potency with an half maximal effective concentration (EC50)
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of AnCoA4 by treating cells with compounds related to An-
CoA4 and measuring NFAT luciferase expression. AnCo4882,
which also differs from AnCoA4 only by a methoxy group,
showed almost complete inhibition at 20 mM. 12a-Epimilleto-
sin, which has a more sterically hindered structure and a hy-
droxyl replacement of the double bond on carbon 3, also
demonstrated strong inhibition at 20 mM. Biochanin A showed
a weaker dose-dependent inhibition, while removing all the
methoxy groups to generate genistein abolished all activity.
Methylation and addition of an ethyl ester in 2574 ISO restored
some of the activity to genistein (Figure 1K). On the basis of
these findings, we determined that the core structure required
for activity is composed of an isoflavone-like structure contain-
ing three rings. The aromatic ring C tolerates small methoxy
substituents, while the aromatic ring A can accept a phenyl
ring (Figure 1L). Addition of large groups on ring B seemed
to reduce activity of the analogs. This suggests that the best
site for modifying this class of molecules to generate additional
Orai1 inhibitors would be on the aromatic ring A. We have
since made several synthetic analogs to enhance the potency
and drug-likeness of this class of inhibitors (Figure S2). An-
CoA4 remained the best inhibitor for our studies, as most of
the analogs were less potent or had lost their ability to inhibit
SOC at all.
AnCoA4 Inhibits SOC-Induced Calcium Influx
To further confirm the validity of our binding screen, we next
investigated whether AnCoA4 inhibits NFAT activity by inhibiting
the calcium influx pathway of SOC. We first tested whether An-
CoA4 acts through inhibition of calcineurin, a phosphatase that
is activated by binding to calcium upon activation of SOC. Calci-
neurin is responsible for dephosphorylation of NFAT and its
translocation to the nucleus. Ectopic expression of a constitu-
tively active calcineurin blocked the ability of AnCoA4 to inhibit
the luciferase signal, suggesting that AnCoA4 acts upstream of
calcineurin (Figure S3). Because calcium is the direct activator
of calcineurin and it permeates the cell membrane through
Orai1, we measured SOC-specific calcium influx using Fura-2
to measure SOC elevations in HEK293T cells in the presence
(50 mM) or absence of compounds identified from the secondary
screen. AnCoA4 nearly abolished SOC-dependent intracellularFigure 1. SMM Screen and Validation of Potential Inhibitors of SOC by
(A) Schematic of SMM screen. Purified GST-fusedMFDswere incubated with SMM
using fluorescent-tagged anti-GST antibody.
(B) Scatterplot of normalized Z scores for the binding of the small molecules to MF
GST-fused Orai1 MFDs. Gray dots represent background binding. Blue dots a
compounds that bound to MFDs with high affinity on the basis of their Z scores.
(C) Histogram of replicate-averaged Z scores of hit compounds with background c
Red bars represent consistent tight binding molecules to MFDs that were picked
(D) Fifty-one selected compounds were tested for inhibition of SOC-dependent
NFAT-luciferase inhibitionwith normal cell viability are highlighted in red rectangle
and (-) represents no addition of TG and PMA for activation of NFAT-luciferase. Al
represent SEM.
(E) Viability measurements using Renilla luciferase activity driven by SOC-indepe
(F–I) Dose-response measurements of NFAT-luciferase activity shows mild inhibi
correlated dose-response for AnCoF6 (H), and AnCoA4 (I).
(J) Dose-response curve of AnCoA4 calculated from (I). The calculated EC50 is 0
(K) Analogs of AnCoA4: AnCo4882 (+)-12a-epimilletosin, biochanin A, genistein,
(L) Core active structure (red) and predicted suitable constituents determined fro
Chemistry & Biology 21, 1278–1calcium influx compared with DMSO-treated control (Figures
2A and 2B), while AnCoF6 caused a significant reduction in the
calcium rise (Figure 2C). In agreement with the results from the
luciferase screen, AnCoA5 and AnCoG4, which have very
different chemical structures from AnCoA4, were not as effective
at inhibiting SOC (Figures 2D and 2E). The analogs of AnCoA4
also inhibited calcium influx, with AnCo4882 having the most
potent effect (Figures 2F and 2G), followed by 12a-epimilletosin
(Figure 2H) and biochanin A (Figure 2I). To exclude the possibility
that these compounds inhibit SOC by preventing the depletion of
calcium stores, we measured the release of calcium from the ER
directly. We saw no evidence of the compounds’ inhibiting the
release of calcium from the ER in the absence of extracellular
calcium (Figure 2J).
AnCoA4, AnCoF6, and AnCoA5 also caused a significant
decrease in the influx slope of the intracellular calcium elevation,
providing additional evidence that they inhibit calcium influx
rather than release of calcium from stores. Surprisingly, AnCoG4
caused a modest increase in the slope of the calcium rise, sug-
gesting that it increases calcium flux through the channel (Fig-
ure 2K). Finally, all of the analogs of AnCoA4 caused a significant
decrease in the slope of influx (Figure 2L). Together, these results
suggest that the compounds identified by theMFD screen inhibit
SOC influx in cells. To gain some insight about the specificity of
these compounds for SOC, we also tested the effect of these
compounds on voltage-gated calcium channels in SH-SY5Y
cells. Although we recognize that enhancement of potency and
specificity is a challenging task that comes after hit identification
in a screen, it was encouraging to observe that AnCoA4 (10 mM)
had no effect on voltage-gated calcium channels, supporting the
idea that AnCoA4 is relatively specific for SOC (Figure S4).
To provide direct evidence that AnCoA4 inhibits Orai1 chan-
nels, we performed whole-cell patch-clamp recordings in a
HEK293 cell line stably coexpressing STIM1 and Orai1. After
depletion of calcium stores, cellsmaintained a relatively constant
level of CRAC current (ICRAC) over 1,000 s. Acute application of
20 mM AnCoA4 resulted in an 80% decrease in calcium currents
(Figures 3A–3C). The inhibitionwas dose dependent butwas only
partially reversed by removing the compound, pointing to a slow
effective off rate of AnCoA4 from the channel. AnCoA4 did not
alter the current-voltage relationship of ICRAC, indicating that it
does not change the channel’s ion selectivity (Figure 3D).NFAT-Luciferase
s, and binding ofMFDs to surface-immobilized small molecules was detected
Ds. Each axis represents an independent SMM replicate treated with a pool of
re true test compounds with low binding, and red dots represent chemical
orrection. Blue bars show low affinity and nonspecific small-molecule binders.
as potential hits for follow-up studies.
NFAT-luciferase activity in HEK293T cells. Compounds exhibiting significant
s. Each number represents a compound, (+) represents DMSO treatment alone,
l measurements were taken 6 hr after the addition of TG and PMA. All error bars
ndent promoter.
tion for AnCoA5 (F), inhibition at highest concentration for AnCoG4 (G), a well-
.88 mM.
2574 ISO were tested using NFAT-luciferase assay to determine SAR.
m SAR studies.





Figure 2. AnCoA4 and Its Commercial Analogs Inhibit SOC-Dependent Calcium Influx
(A) SOC-mediated calcium influx quantified by ratiometric Fura-2 imaging in cells treated with 0.1%DMSO. TG application induced a transient calcium rise due to
ER store depletion followed by sustained SOC-mediated calcium influx upon readdition of 2 mM calcium to extracellular medium. All error bars represent SEM.
(B–E) SOC-mediated calcium influx is reduced significantly by 50 mM AnCoA4 (B) or 50 mM AnCoF6 (C) and reduced mildly by 50 mM AnCoA5 (D), with no
observed reduction by 50 mM AnCoG4 (E).
(F–I) SOC-mediated calcium influx is inhibited by analogs of AnCoA4. Compared with 0.1% DMSO (F), SOC-mediated calcium influx is significantly reduced by
treatment with 50 mM AnCo4882 (G), 50 mM (+)-12a-epimilletos (H), or 50 mM biochanin A (I).
(J) AnCoA4 does not alter ER store depletion. AnCoA4 (red), AnCoF6 (orange), AnCoG4 (green), and AnCoA5 (blue) treatments do not alter calcium rise induced by
TG-mediated store depletion compared with DMSO (black).
(K) Selected hits from the screen reduce the slope of SOC-dependent calcium influx. Bars represent the measured slopes from SOC calcium rise of Fura-2
imaging in (A)–(E).
(L) Analogs of AnCoA4 reduce the slope of SOC-dependent calcium influx. Bars represent the measured slope from SOC calcium rise of Fura-2 imaging in (F)–(I).
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Figure 3. Electrophysiological Characterization of ICRAC Inhibition by AnCoA4 in HEK293 Cells Stably Coexpressing STIM1 and Orai1
(A) AnCoA4 inhibits ICRAC in a dose-dependent manner. TG-induced currents were monitored using a voltage clamp over time. DMSO (star), AnCoA4 at 10 mM
(circle) and at 20 mM (square) of AnCoA4 were added at indicated time points. A representative current trace from a DMSO-treated cell is shown in gray.
(B) Acute application of 20 mM AnCoA4 significantly reduced current densities of activated channels compared with DMSO-treated control condition. Each dot
represents the current amplitude measured 5 min after the addition of DMSO or AnCoA4. All error bars represent SEM.
(C) ICRAC amplitude of each AnCoA4-treated cell plotted as the percentage of ICRAC amplitude before the application of AnCoA4 from (B).
(D) Representative current-voltage (I-V) relationship plotted for cells acutely treatedwith 0.1%DMSO (star), 10 mMAnCoA4 (circle), and 20 mMAnCoA4 (square) in
2 mM calcium bath from (A). AnCoA4 shows inhibition of ICRAC without affecting gating properties.
(E) Representative I-V curves from cells pretreated with 5 mM AnCoA4 (square) or 0.1% DMSO (star) for 10 min, then allowed to develop ICRAC in a 2 mM calcium
solution.
(F) Cells pretreated with AnCoA4 (5 mM) show markedly reduced ICRAC compared with DMSO-treated control cells. Each dot represents the current amplitude
recorded from a single cell. *p < 0.01.
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by the activation state of the channel by treating cells with An-
CoA4 before activation of Orai1 and then measuring the current.
Although vehicle-treated cells developed up to 200 pA of cur-
rent, cells pretreated with 5 mMAnCoA4 developed no current at
all (Figures 3E and 3F). Compared with the 20 mM concentration
required for postactivation treatment, these results revealed a
dramatic increase in potency when applied before channel
activation, suggesting that AnCoA4 is more effective when it is
administered before STIM1 starts interacting with Orai1.
AnCoA4 Binds Directly to Orai1
Our results strongly suggested that AnCoA4 binds and inhibits
Orai1, but the exact binding site was not apparent. To address
this question, we used a fluorescence aggregation assay that
measures the binding of small molecules to a recombinant
mCherry-fused protein. In this assay, protein aggregation
quenches the mCherry fluorescence; compounds that bind to
the protein increase fluorescence by preventing mCherry aggre-
gation and quenching. We found that AnCoA4 increased the
fluorescence of the C terminus of Orai1 fused to mCherry but
had no effect on the N terminus or the 2-3 loop of Orai1 fused
to the same protein (Figure 4A). We also used surface plasmon
resonance (SPR) to measure the direct binding of AnCoA4 to
different domains of Orai1 and found robust concentration-
dependent binding to the C terminus of Orai1 and essentiallyChemistry & Biology 21, 1278–1no binding to the 2-3 loop and N terminus of Orai1 protein (Fig-
ure 4B). The apparent affinity of AnCoA4 was weaker than the
EC50 determined in cells, possibly because the protein frag-
ments are incompletely folded in buffer where hydrophobic
plasma membrane provides additional binding affinity for the
compound in the native context of the cell. Overall, these two
experiments suggest that AnCoA4 binds directly to Orai1, prefer-
entially to the C terminus.
The recent publication of the crystal structure of Drosophila
Orai1 as well as our investigation of the structure function rela-
tionship of AnCoA4 made it possible for us to use computa-
tional methods to gain additional insights into AnCoA4 binding
to Orai1(Hou et al., 2012). We used the FRED docking algo-
rithm to look for binding sites on a homodimer of Orai1 and
identified two putative binding sites (Figure 4C). One site in
the main cavity encompasses a region that lacks 16 amino
acids in the crystal structure, so we did not pursue it further.
The second binding site for AnCoA4, however, lies in the inter-
face between the C termini of neighboring Orai1 dimers and is
composed of the polar contacts His299, Glu318, Thr312, and
possible pi-pi and hydrophobic interactions with Phe300 (Fig-
ures 4D–4F). These residues are conserved in the human
Orai1 protein, suggesting that this could be the binding site
for the human protein. It is worth noting that AnCoA4 was
not cocrystallized with Orai1, and docking only provides a





Figure 4. AnCoA4 Binds to a Single Putative Binding Site on Orai1 C Terminus and Perturbs STIM1-Orai1 Interaction
(A) AnCoA4 binds strongly to the C terminus of Orai1. Increased mCherry fluorescence represents a reduction in MFD aggregation-induced quenching. AnCoA4
significantly reduces aggregation of Orai1 C terminus but not 2-3 loop or N terminus.
(B) SPR analysis of binding of the Orai1 N terminus (black), 2-3 loop (blue), and C terminus (red) at various concentrations of AnCoA4.
(C) Architectural representation of the intracellular view of Orai1 (D.melanogaster) hexameric channel. Red and blue ribbons represent the putative C termini of the
first and second Orai1 subunits in a single homodimer. AnCoA4 is shown in a putative binding site of only one homodimer out of three (black rectangle).
(D) Side view of a single homodimeric subunit of Orai1 with AnCoA4 putative binding site in the C-terminal arms.
(E) Zoomed-in view of putative binding of AnCoA4 in the C-terminal interface of two Orai1 Fragments.
(legend continued on next page)
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because modifications to the central ring (ring B) of isoflavone
AnCoA4 render the molecule inactive. Furthermore, highly
polar groups added to ring A of AnCoA4 that interfere with hy-
drophobic interactions decrease the inhibition. Interestingly, in
AnCoA4, the western benzodioxole group is rotated relative to
the core isoflavone, which likely facilitates the other polar inter-
action with Gln269. Molecules with this rotation hindered such
as epimilletosin show reduced potency.
We also used mutagenesis of Orai1 to identify residues
involved in direct binding to AncoA4.Wemade over 30mutations
in the C terminus of Orai1 and investigated whether these
mutations prevented inhibition of the channel by AncoA4. Two
mutations, S263M and L273I, resulted in a modest reduction of
AncoA4 inhibition, while the rest had either no effect or
completely eliminated activation of the channel (Figure S5).
Combining the two functional mutations eliminated the activity
of the channel completely, so it was not possible to determine if
theywould have combined synergistically. These results suggest
that AncoA4 is likely to bind directly to the C terminus of Orai1.
AnCoA4 Perturbs the Interaction between STIM1 and
Orai1
Because the C terminus of Orai1 is an important binding site
for STIM1, we asked if AnCoA4 could inhibit the binding of
STIM1 to Orai1. STIM1 forms puncta and recruits Orai1 to
plasma membrane ER junctions following depletion of internal
calcium stores (Liou et al., 2005; Mercer et al., 2006; Zhang
et al., 2005). We therefore generated a stable cell line express-
ing Orai1-GFP and mCherry-STIM1, depleted calcium stores
using TG, and monitored the formation of puncta in presence
or absence of AnCoA4 (Figure S6). Although the number of
STIM1 puncta and Orai1 puncta were unchanged, we noticed
a decrease in the intensity of Orai1 puncta in the presence of
AnCoA4 (Figures 4G and 4H). When we quantified the fluores-
cence intensity of Orai1-GFP and mCherry-STIM1 in each
punctum, we found that the presence of AnCoA4 did not affect
the intensity of STIM1 fluorescence in puncta but significantly
decreased Orai1 fluorescence intensity (Figure 4I). This change
in the ratio of Orai1 to STIM1 suggested that the number of
Orai1 molecules present for every STIM1 molecule is signifi-
cantly lower in the presence of AnCoA4. Orai1 recruitment to
STIM1 was also delayed in the presence of AnCoA4, which
suggests that AnCoA4 reduces the affinity of Orai1 for STIM1
(Figure 4J).(F) Stick representation of amino acids surrounding (within 4 A˚) themost favorable
amino acids are labeled in black. Important corresponding human amino acids a
(G) AnCoA4 treatment does not affect STIM1 puncta formation. HEK293 cells we
time zero, 1 min before the addition of TG. Images collected at minute 6 were th
(H) AnCoA4 treatment does not affect Orai1 puncta formation. Cells were treated
zero, 1 min before the addition of TG. Images collected at minute 6 were then ta
(I) AnCoA4 treatment reduces the number of Orai1 molecules in each puncta. Eac
(n = 820) in DMSO-treated cells and AnCoA4-treated cells (50 mM, n = 525). *p < 0
(J) Cells treated with AnCoA4 exhibit a reduced number of Orai1 molecules per
AnCoA4 (50 mM) was added at time zero, 1 min before the addition of TG at min
(K) AnCoA4 inhibits the constitutively active Orai1 (V102C), independent of ST
Figure 1. HEK293T cells were transfected with Orai1 (V102C) in absence of STIM
(L) Overexpression of Orai1 shifted the EC50 curve relative to endogenous levels
trations (log[Orai1 mM]) were used to plot and calculate EC50 values.
Chemistry & Biology 21, 1278–1The C terminus of Orai1 not only binds to STIM1 but also plays
an important role in the opening of the channel (Frischauf et al.,
2011). We therefore asked whether AnCoA4 can inhibit Orai1
independently of STIM1. We expressed a mutant of Orai1,
V102C, which is constitutively active in the absence of STIM1
and treated cells with AnCoA4 (McNally et al., 2012). We found
that AnCoA4 inhibited the constitutively active channel, suggest-
ing that in addition to reducing the affinity for STIM1, AnCoA4 in-
hibits Orai1 directly (Figure 4K). These results are consistent with
the idea that AncoA4 binds to a region of Orai1 that both controls
channel gating and interacts with STIM1. To provide further
confirmation for this idea, overexpression of Orai1 shifted the
EC50 of AnCoA4 curve to the right, suggesting that AnCoA4
binds to the channel directly (Figure 4L). Additionally, overex-
pression of STIM1 almost completely prevented AnCoA4 inhibi-
tion of the channel, suggesting that STIM1 and AnCoA4 compete
for the same binding site on Orai1 (Figure S7).
AnCoA4 Inhibits Genes Involved in T Cell Activation
The ability of AnCoA4 to potently suppress activation of an NFAT
reporter gene suggests that it blocks one of the major transcrip-
tional pathways that regulate T lymphocyte activation. To deter-
mine if AnCoA4 also suppresses the expression of relevant
endogenous genes, we used quantitative RT-PCR (qRT-PCR)
to measure the expression of 80 genes that play key roles in
T cell activation (Figure 5A). We stimulated Jurkat T cells with
phytohemagglutinin (PHA), a lectin and a commonly used acti-
vator reagent of T cells, in the presence of AnCoA4 (10 mM)
and observed a downregulation of 83% of the genes associated
with T cell activation. This subset included IL2, IL3, and TNF, as
well as a number of chemokine receptor genes necessary for
T cell migration and extravasation. These results indicated that
AnCoA4 can inhibit the expression of endogenous genes that
are required for activation of T lymphocytes.
To determine if AnCoA4 primarily affects genes that are regu-
lated by calcium, we compared the effects of AnCoA4 with the
effects of CsA, a calcineurin inhibitor. We found that AnCoA4
decreased the expression of most but not all of the same genes
as CsA, including IL2, CD27, NFATC1, TNF, TBX21, CSF,
ICOS, and CXCR3 (Figure 5B). AnCoA4 inhibited fewer genes
than CsA but suppressed other genes, such as IL18, that are
unaffected by CsA exposure. These data suggest that AnCoA4
could be a more effective inhibitor than CsA in physiological
processes that involve IL18. It also shows that molecules
such as AnCoA4 and CsA could be used in combination toconformation of AnCoA4 (green structure) in its putative binding site.Drosophila
re labeled in parentheses.
re treated with 0.1% DMSO (black, n = 7) or with 50 mM AnCoA4 (red, n = 9) at
en taken for analysis. All error bars represent SEM.
with 0.1% DMSO (black, n = 25) or with 50 mM of AnCoA4 (red, n = 24) at time
ken for analysis.
h bar represents the average of mean fluorescence intensity for each punctum
.01. Compound treatment was performed according to protocols in (G) and (H).
STIM1 molecule in each punctum (red) compared with DMSO control (black).
ute 1.
IM1. Orai1 (V102C) activity was assayed using NFAT-luciferase assay, as in
1 and treated with AnCoA4.
of Orai1 and rescued the inhibitory effects of AnCoA4. Log of Orai1 concen-
292, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1285
AB
C
Figure 5. AnCoA4 Has a Robust Effect on Gene Expression of Activated T Cells
(A) AnCoA4 treatment effects expression of T cell activation mediating genes in Jurkat T cells. Fold change in PHA-activated induction of genes for AnCoA4-
treated cells over DMSO-treated control is plotted.
(B) AnCoA4 treatment downregulates known T cell-activating genes. Compared with DMSO-treated cells (black), treatment with AnCoA4 (10 mM) (red) and CsA
(50nM) (blue) reduced mRNA levels of T cell-activating genes.
(C) AnCoA4 and CsA have similar effects on gene expression. Gene expression heatmap of 10 mMAnCoA4-treated (bottom row) and 50 nM CsA-treated (middle
row) Jurkat T cells. The gene profile of SOC-deficient Jurkat T cells (CJ1, top row) is shown for comparison. Green and red colors indicate down- and upre-
gulation, respectively. Assayed genes include general markers of T cell activation (black), Th1-affiliated (green) and Th2-affiliated (blue) genes, and putative
immunosuppressive genes (red).
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ical conditions.
We next compared the gene expression profile of cells
treated with AnCoA4 and the gene expression profile of the
CJ1 Jurkat T cell line, which lacks a functional STIM1 protein
and therefore SOC (Figure 5C) (Park et al., 2010). Knockout
of STIM1 reduced the expression of approximately twice as
many genes as AnCoA4 or CsA, indicating that a complete1286 Chemistry & Biology 21, 1278–1292, October 23, 2014 ª2014 Eabolishment of SOC has a much broader impact on T cell acti-
vation and function.
AnCoA4 Effectively Inhibits the Immune Response
in Vitro and in Vivo
The ability of AnCoA4 to reduce the expression of genes that
participate in T cell activation suggests that it may be an effective
immunosuppressant. To test this idea directly, we used thelsevier Ltd All rights reserved
Chemistry & Biology
Identification of a Class of CRAC Inhibitorsmixed lymphocyte reaction (MLR), in which fluorescently labeled
lymphocytes of one strain of mouse are mixed with lymphocytes
(irradiated splenocytes) of an allogeneic mouse strain in vitro. In
this assay, exposure of T cells to allogeneic cells triggers cell
proliferation that can be monitored by measuring the dilution of
fluorescently labeled cells as they divide (Figure 6A). Treatment
of the proliferating cells with either 10 or 50 mM of AnCoA4 twice
a day for 7 days inhibited cell proliferation by 90% relative to
control. This is similar to what is observed with treatment of
CsA, with the caveat that CsA is more potent than AnCoA4
(Figure 6B; see Table S1 for p values). Interestingly AnCoA4
seemed to be somewhatmore persistent than CsA in cell culture,
probably because of its hydrophobicity.
To examine the effect of AnCoA4 in vivo, we used a modified
ovalbumin-induced, delayed-type hypersensitivity (DTH) model
(Black, 1999;Lamontet al., 1989;Mu¨ller etal., 2002). In thismodel,
animals are primed by dorsal subcutaneous injection of complete
Freund’s adjuvant (CFA) mixed with ovalbumin (ova). Three days
later, mice are challenged with ova with or without incomplete
Freund’s adjuvant (IFA) by injection into the footpad. This local
exposure of ova results in the proliferation of lymphocytes, partic-
ularly in the popliteal lymph nodes, which are harvested and
analyzed after six days (see Experimental Procedures).
Mice were injected intravenously with or without AnCoA4 4 hr
before and three injections after the test injection of ova into the
footpad. All mice appeared to tolerate the drug well, showing
no apparent indications of sickness or acute toxicity throughout
the 6 days of the experiment. Harvesting of the popliteal lymph
nodes showed that mice treated with AnCoA4 and CsA had
significantly smaller popliteal lymph nodes than vehicle-treated
animals (Figure 6C). Quantification of these results confirmed
that both AnCoA4 and CsA decreased the cellularity of lymph
nodes consistent with their role as immunosuppressant agents
in vivo (Figure 6D).
We designed a second study to determine if AnCoA4 could
prevent T cell activation without pretreatment of the animal (Fig-
ure 6E). Histological evaluation of the footpads showed that
vehicle-injected mice had a robust local inflammatory response
involving both the footpad and underlying structures. This
response consisted of both primary lymphohistiocytic inflamma-
tion and extensive secondary neutrophil infiltration and tissue
damage (Figures 6F and 6G). AnCoA4-treated animals showed
a greatly reduced lymphohistiocytic inflammationwith no neutro-
phil and tissue damage (Figures 6H and 6I) and blind scoring of
the histological sections confirmed that both AnCoA4 and CsA
reduced the degree of local inflammation in OVA-injected foot-
pads. In contrast, local injection of IFA in the footpad caused a
robust innate immune response that was not blocked by AnCoA4
or CsA, indicating that these two immunosuppressant agents
could have the potential to selectively block T cell-mediated
responses (Figure 6J). Further studies are needed to fully charac-
terize the specific effects of AnCoA4 on different classes of
immune cells, but it is clear from our studies that AnCoA4 can
inhibit T cell activation and proliferation in vivo.
DISCUSSION
In this study, we identified a small-molecule blocker for SOC
channels by taking advantage of the structural knowledgeChemistry & Biology 21, 1278–1gained by studying its two major constituents, STIM1 and
Orai1. By using MFDs of Orai1 and STIM1 to search for mole-
cules that bind to the functional domain of the channel, we
identified 4 compounds from a collection of 12,000 that were
capable of inhibiting Orai1. One of these compounds, AnCoA4,
binds directly to the C terminus of Orai1, blocks the expression
of calcium-regulated genes that control T cell activation and in-
hibits T cell-mediated immune responses in vivo. Blockers of
SOC channels, and of Orai1 in particular, are promising for a
number of therapeutic areas, including immunomodulation,
inflammation, and thrombosis. A clear understanding of the
mechanism of action and binding site of AnCoA4, along with
its ability to inhibit T cell activation in vitro and in vivo, makes
it a useful new tool for studying the role of CRAC channels in
the immune system. Our knowledge of the mechanism of ac-
tion of AnCoA4 has already proved useful for the rational
design of more effective analogs with improved potency and
specificity.
Our characterization of AnCoA4 provides interesting insights
into the mechanism of CRAC channel activation. The C terminus
is an established target for Orai1; however, the N terminus also
binds to STIM1 and is important for gating and activation of
the channel. By binding directly to the C terminus of Orai1, An-
CoA4 effectively blocks the channel and inhibits recruitment of
STIM1. AnCoA4 appears to work more efficiently when applied
prior to the recruitment of STIM1 to Orai1, suggesting that it
competes with STIM1 for a binding site on the C terminus of
the channel. More surprisingly, AnCoA4 can inhibit Orai1 activa-
tion even in the absence of STIM1, as indicated by its ability to
inhibit a constitutively active channel. These findings suggest
that AnCoA4 and STIM1 bind to similar regions of the C terminus
of Orai1.
AnCoA4 was also effective at inhibiting DTH reaction in vivo.
Because of its low solubility, it had to be formulated such
that it would not precipitate upon injection. This low solubility,
along with its chemical stability, had the unexpected benefit
of providing long-lasting immunosuppression over a period of
days. Despite this long-lasting effect, AnCoA4 was not toxic to
animals even at high doses.
Importantly, we identified AnCoA4 using a method for drug
discovery that, until now, had not been applied to ion channels.
Historically, small-molecule screens for ion channel blockers
have used heterologous cell lines expressing nonphysiological
levels of ion channels, combined with intracellular calcium
dyes to measure the activity of the channel. Although this
approach has been as effective, it also presents some practical
challenges. As a first-line approach, cell-based assays are
resource intensive and yield a large number of off-target hits.
This process then requires follow-up studies to characterize
and validate all hits, which makes the process somewhat
cumbersome and expensive. Because the molecular target
and mechanism of action of compounds identified in cell-based
assays are often unknown, structural activity based optimization
of these compounds using traditional medicinal chemistry
has been challenging. Cell-based assays also tend to exclude
potentially useful lead compounds that could bind to intracellular
regions of a channel but have low cell permeability or low affinity.
In this study, we developed a cell-free method to screen





Figure 6. AnCoA4 Inhibits T Cell Responses in MLR and In Vivo DTH Model
(A) AnCoA4 inhibits proliferation in MLR. FACS plots of proliferating T cells labeled with CFSE, a plasma membrane-labeling dye, are shown. Cells in (-)control
were not stimulated (top left), whereas cells in (+)control were stimulated with irradiated allogeneic splenocytes. Treatment conditions are shown above each
FACS plot.
(B) Summary of effect of AnCoA4 on mixed lymphocyte proliferation from (A). Cells stimulated with allogeneic splenocytes were treated with 10 mM of AnCoA4
(orange), 50 mM of AnCoA4 (red), and 50 nM of CsA. Each bar represents the quantification of percentage proliferation by indicated dose regimen. All error bars
represent SEM.
(C and D) AnCoA4 treatment reduces lymphocyte proliferation in vivo. Dissected popliteal lymph nodes from vehicle-treated (top), AnCoA4-treated (middle), and
CsA-treated (bottom) mice are shown (C). AnCoA4 treatment reduces the node size as well as number of cells per lymph node (D). Each dot represents one lymph
node (see Experimental Procedures).
(E) Schematic of AnCoA4 and ova injection schedule for in vivo DTH studies.
(F–I) AnCoA4 treatment attenuates local inflammatory response. Histological representation of paw cross-sections stained with hematoxylin and eosin. Vehicle-
injected mice exhibit a robust local inflammatory response involving the foot pad and underlying structures (black arrowheads, F). A magnified representation of
the black square from (F) shows primary lymphohistiocytic inflammation (arrowheads) with extensive secondary neutrophil infiltration with tissue damage (as-
terisks, G). AnCoA4 treatment leads to a greatly attenuated response limited only to the footpad (black arrowheads, H), with only moderate lymphohistiocytic
inflammation and no or minimal secondary neutrophil accumulation apparent in magnified view (I).
(J) Histological scoring of foot pad inflammation. Each bar represents histological grading for a single treatment containing paws from four or five mice per group
(see Experimental Procedures). *p < 0.05.
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Identification of a Class of CRAC Inhibitorsregions of Orai1 and STIM1. As structural information about ion
channels is now widely available, it should be possible to design
screens to target not only specific ion channels but specific func-
tionsof ion channels that aremediatedby specificdomains.Apo-
tential limitation of our approach is that channel fragments may
not fold into their native tertiary structure in solution and thus
might not behave as in the intact channel. We mitigated this
risk by selecting the CAD and the C terminus of Orai1, both of
which can modulate the activity of the channel when introduced
into intact cells (Mullins et al., 2009; Park et al., 2009). This
method therefore provides us with the ability to screen for com-
pounds inexpensively andquickly, resulting in hitswhere aknown
binding site and mechanism of action can facilitate structural
optimization.
SIGNIFICANCE
SOC entry is required for activation of immune cells, and its
lack of function causes SCID in human patients. In lympho-
cytes, this process is mediated through the Orai family of
calcium channels, which are activated by direct binding to
STIM proteins that act as calcium sensors in ER. SOC has
recently been shown to play a major role in several other
physiological and pathological processes, ranging from
muscle development to cancer. It is now clear that SOC
components are ubiquitously expressed in variety of tis-
sues, severing diverse functions. Abnormal overactivation
of immune response causes autoimmune disorders, and
the lack of safe and long-term treatments has created the
need for novel and improved immunosuppressant agents.
Pharmacological blockers of SOC channels provide us
with tools to further examine the physiological role of
SOC and could ultimately allow the development of poten-
tial treatments of autoimmune disorders. We have de-
signed a platform methodology for generating SOC
blockers on the basis of identification and targeting MFDs
of STIM1 and Orai1. AnCoA4, a small-molecule blocker
that inhibits SOC at submicromolar concentrations, was
identified using this methodology. AnCoA4 binds directly
to the C terminus of Orai1 and blocks calcium influx inde-
pendent of binding to STIM1. It also reduces the affinity
of STIM1 for Orai1 and inhibits T cell activation both
in vitro and in vivo. AnCoA4 confers selectivity to Orai1
over L-type calcium channels, but further examination of
specificity is required to understand the off-target liabilities
of this molecule. This process, coupled with medicinal
chemistry and structural-activity relationship studies, could
result in lead molecules for development of useful clinical
reagents.
EXPERIMENTAL PROCEDURES
Composite Z Score Calculation
Median values were calculated for all mock spots on each SMM to produce a
trimmed mock distribution population. The mean of the trimmed mock distri-
bution was then subtracted from each sample spot on the same SMM to pro-
duce background subtracted values. These values were then divided by twice
the SD of the trimmed mock measurements to give Z scores. Cosine correla-
tion analysis of Z scores was then used to determine a composite Z score for
each sample spot.Chemistry & Biology 21, 1278–1Protein Expression and SMM
All fusion proteins (Orai1-NT [1–91], II-III loop [142–177], CT [255–301], and
STIM1-CAD128 [342–469]) used for screens and binding assay were con-
structed in pGEX6p plasmids (Invitrogen) transformed, produced, and puri-
fied from BL21 bacteria according to the manufacturer’s instructions.
SMMs were screened and data were analyzed according protocols described
previously in collaboration with the Broad Institute (Seiler et al., 2008; Vegas
et al., 2008).
Cells and Transfection
HEK293 and HEK293T cells (ATCC) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) with GlutaMax (GIBCO), 10% fetal bovine serum
(Hyclone). A HEK293 cell line with an inducible mcherry-STIM1-T2A-Orai1-
eGFP and mcherry-STIM1-T2A-myc-Orai1 were generated with the T-REx
system (Invitrogen) and were maintained with 100 mg/ml hygromycin. Cells
were transfected at 90% confluency with 0.2 to 0.5 mg DNA using Lipofect-
amine 2000 (Invitrogen) according to the manufacturer’s instructions.
NFAT-Luciferase Assays
HEK293T cells were cotransfected with the indicated constructs and an NFAT
reporter gene (firefly luciferase gene C-terminal to a 4X-NFAT site from the IL-2
gene). Cotransfection with theRenilla luciferase gene (pRLTK) driven by the TK
promoter was used to control for cell number and transfection efficiency. After
12 to 18 hr, cells were treated with a control DMSO solution (mock), phorbol
12-myristate 13-acetate (PMA; 1 mM), or PMA + TG (1 mM) for 6 hr. Assays
were performed with the Dual Luciferase Reporter Assay System (Promega).
For each condition, luciferase activity was measured with four samples taken
from duplicate wells with a 96-well automated luminometer (Turner Bio-
systems). Results are represented as the ratio of firefly to Renilla luciferase
activity.
MTT RBL Viability Assay
RBL cells were plated in 96-well plates at 10,000 cells per well (100 ml/well).
Twenty-four hours later, DMSO (2%, vehicle control) and AnCoA4 compound
at the indicated concentrations were added in 3 wells (100 ml/compound or
DMSO). Twenty-four hours later, 20 ml of MTT (0.5mg/mL, thiazolyly blue tetra-
zolium bromide, Sigma, M5655) was added to each cell media for 4 hr. Two
hundred microliters of 100% DMSO was added in each well. Cell lysates
was measured with Microplate Reader (SpectraMax 190, Molecular Devices)
at 595 nm. Background was subtracted. The percentage of cell survival was
calculated using the following formula: cell survival (%) = (absolute of com-
pound/absolute of control) 3 100. Three replicate wells were measured at
each compound concentration and experiments were performed at least three
times.
Confocal Microscopy
HEK293 cells were plated onto sterilized coverslips coated with poly-D-lysine
and transfected and maintained in complete DMEM for 12 to 18 hr before
imaging in Tyrode’s solution, containing 129 mM NaCl, 5 mM KCl, 2 mM
CaCl2, 1 mM MgCl2, 30 mM D-glucose, and 25 mM Na-HEPES (pH 7.4).
For depletion of stores, cells were treated with 1 mM TG Tyrode’s solution
for 6 min. Fluorescence emission was collected at 610 nm (mCherry) and
530 nm (eGFP). All experiments were performed at 22C to 25C. Images
were collected with the UltraVIEW VoX confocal microscope (PerkinElmer) us-
ing a-plan Apochromat 63x/NA1.4 oil immersion objective and analyzed using
Volocity 5 software (Improvision). To measure total puncta area per cell, punc-
tum was defined as any clusters with normalized SDs higher than the back-
ground intensity whose size was limited to larger than 0.2 and smaller than
5 mm in area. The sum of the area of all puncta was then divided by each cell’s
area. To measure empirical ratio of Orai1 to STIM1 molecules, each punctum
was picked manually as a region of interest, and the fluorescence of Orai1 and
STIM1 was measured within that punctum over time.
Fura-2 Calcium Imaging
Cells were loaded at 37C in DMEMwith 1 mM fura-2 AM for 30 min. Ratiomet-
ric Ca2+ images were collected with a Nikon Eclipse 2000-U inverted micro-
scope using Open Lab 5 software (Improvision) and analyzed using Igor Pro
6 software (Wavemetrics).292, October 23, 2014 ª2014 Elsevier Ltd All rights reserved 1289
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HEK293 cells expressing equimolar levels of mCherry-STIM1 and myc-Orai1
were induced and incubated by tetracycline for 14 to 18 hr in DMEM. Currents
were recorded via standard whole-cell patch-clamp techniques (Prakriya and
Lewis, 2001). Pipettes of resistance 3 to 5 MU were filled with an internal
solution containing 150 mM Cs aspartate, 8 mM MgCl2, 10 mM EGTA, and
10 mM HEPES (pH 7.2 with CsOH). Currents were sampled at 5 kHz and
filtered at 2 kHz, and all voltages were corrected for the junction potential of
the pipette solution relative to Ringer’s in the bath (13 mV).
SPR
Orai1-NT (48–91), 2-3 loop (142–177), CT (255–301), the polypeptides were
used as an immobilized ligand and dissolved in 10 mM sodium acetate buffer
(pH 5.0). PBS (13, 10 mM PO4, 138 mM NaCl, 2.4 mM KCl, pH 7.4) was pre-
pared from 10 3 PBS for molecular interaction affinity and solvent correction.
HBS-EP (HEPES buffered saline with 3mM EDTA and 0.005% surfactant P20
[BR-1001-88, Biacore]) and amine coupling reagents (400mM 1-ethyl-3-[3-di-
methylamino-propyl] carbodiimide hydrochloride [EDC, a part of BR-1000-50],
100mMN-hydroxysuccinimide [NHS, a part of BR-1000-50]), and 1MEthanol-
amine-HCl (a part of BR-1000-50), 10 mM sodium acetate buffer (pH 4.0–5.5,
BR-1003-49) were purchased from GE Healthcare. NaOH (50 mM) was used
for regeneration.
The interactions of AnCoA4 with immobilized Orai1 C terminus were studied
by using a Biacore T200 instrument (GE Healthcare). A Sensor S CM5 chips
(BR-1005-30) with carbomethylated dextran covalently attached on the gold
surface was purchased from GE Healthcare.
A flow cell number 2 of a sensor S CM5 chip was first activated by 400 mM
EDC/100 mMNHS and then polypeptide (20 mg/ml) was immobilized by amine
coupling. After washing, a chip was blocked by ethanolamine. In order to do a
binding affinity analysis, AnCoA4 (0, 3.9, 15.625, 31.25, and 125 mM) was eval-
uated with polypeptide immobilized on the flow cell 2 as sample and on the
flow cell 1 as reference using BIAevaluation software (Biacore). The sensor
chip surface was regenerate by 50 mM NaOH regeneration buffer after each
cycle. All experiments were repeated three times. Polypeptide sequences
are described below. Human Orai1 NT amino acid (48–91): SAVTYPDWIGQ
SYSEVMSLNEHSMQALSWRKLYLSRAKLKASS. Human Orai1 2-3 loop
amino acid (142–177): TCILPNIEAVSNVHNLNSVKESPHERMNRHIELAWA.
Human Orai1 C terminus amino acid (255–301): VHFYRSLVSHKTDRQFQEL





The crystal structure of Orai1 calcium channel from Drosophila melanogaster
was obtained from the Research Collaboratory for Structural Bioinformatics
Protein Data Bank (accession number 4HKR). Orai1 is a trimer of homodimers,
and the asymmetric unit of the homodimer is reported in the crystal structure.
Using MacPyMol, the C terminus of both chains of the asymmetric unit was
extracted (beginning with residue I291), to better represent the experimental
system, and this fragment of the protein was used for further study. The ex-
tracted portion of 4HKRwas then loaded into the receptor generation program
Make_Receptor fromOpenEye Scientific, and, as the specific binding site was
unknown, the protein surface was analyzed for concavity to determine poten-
tial binding sites (using the ‘‘molecular’’ probe). One large potential binding site
was identified, and the docking receptor was built using default parameters to
represent this binding site. Before docking, conformers of the ligand AnCoA4
were generated with default parameters using the conformer generation pro-
gram Omega (OpenEye Scientific). This database of conformers was then
docked into the previously generated receptor using the docking program
FRED (OpenEye Scientific), with 20 poses being returned and otherwise
default parameter usage. The top-scoring pose was selected for discussion,
and potential intermolecular interactions between Orai1 and this pose were
highlighted with MacPyMol.
qRT-PCR
mRNA was isolated from Jurkat T cells using RNeasy mini kit (Qiagen). First-
strand cDNA and qRT-PCR was then performed using RT Profiler PCR Array1290 Chemistry & Biology 21, 1278–1292, October 23, 2014 ª2014 ESystems (SABiosciences) according to the manufacturer’s instructions. Anal-
ysis and presentation were performed using Prism software (GraphPad)
Cluster and TreeView software.
MLR
CD4/CD8 conventional T cells (Tcon) were prepared from splenocytes and
peripheral lymph node cells and enriched with anti-CD4 MACS (Miltenyi Bio-
tec) and then anti-CD8 MACS; purity was determined by fluorescence-acti-
vated cell sorting (FACS) on a LSR II or FACS Aria (BD Biosciences), and
cells were mixed so that CD4/CD8 = 2:1. C57BL/6J Tcon (2 3 105) were
labeled with carboxyfluorescein succinimidyl ester (CFSE; Invitrogen) and
added to a 96-well flat-bottom plate containing complete RPMI (Invitrogen)
containing 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin (Invitrogen), and 5 mg/mL 2-mercaptoethanol
(Sigma-Aldrich). For stimulation of Tcon, 106 BALB/c RBC-lysed spleno-
cytes, which had received 30 Gy irradiation, were added. Total volume per
well was 200 ml. After culture at 37C and 5% CO2 for 7 days, cells were re-
suspended and analyzed for proliferation by CFSE dilution on a LSR II (Bec-
ton Dickinson).
In Vivo Mouse Model of DTH
For Figures 6C and 6D, Balb/c mice were immunized subcutaneously
with 50 mg of ovalbumin (Sigma) emulsified with CFA at a 1:1 ratio. Total
volume of injection was 50 ml. Mice were then injected intravenously with
5 mg/kg of AnCoA4 per injection, at 3 3 50 ml/day for 3 days. Vehicle
was composed of 80% PBS, 15% DMSO, and 5% 2-hydroxypropyl-be-
tacyclodextran (Sigma). Ten microliters of emulsified IFA containing 15
ug of ovalbumin was injected in the footpad of each mouse on day 4.
Intravenous dosage of AnCoA4 was at this point increased to 25 mM
at 3 3 50 ml per day (75 mg/kg/day) in 20% DMSO, 10% 2-hydroxy-
propyl-betacyclodextran, 10% benzyl alcohol, and 60% polyethylene gly-
col (PEG). Mice were sacrificed and appropriate tissues harvested on
day 6.
For Figures 6F to 6J, Balb/c mice were immunized subcutaneously with 50
ug of ovalbumin (Sigma) emulsified with CFA at a 1:1 ratio. Total volume of
injection was 50 ml. To monitor innate immunity, 10 ml emulsified IFA contain-
ing 15 mg of ovalbumin was injected in the footpad of each mouse 5 days
later. A different group was injected with 30 ug of ovalbumin only at the
same time to monitor T cell-mediated response. No pretreatment of AnCoA4
starting day 3 was applied in this study, because pf limited availability of An-
CoA4. AnCoA4 (25 mM) was injected intravenously at 3 3 50 ml/day (75 mg/
kg/day) in 20% DMSO, 10% 2-hydroxypropyl-betacyclodextran, 10%
benzyl alcohol, and 60% PEG starting on day 5, as shown in Figure 6E.
Mice were sacrificed, and appropriate tissues were harvested on day. His-
tological inflammation scoring was determined according to the following
guidelines: (1) presence of primary lymphohistiocytosis, (2) primary lympho-
histiocytosis and secondary neutrophil infiltration, and (3) primary lympho-
histiocytosis, secondary neutrophil leakage, and tissue damage. All animal
protocols were approved by the Stanford Administrative Panel on Labora-
tory Animal Care, and the procedures were performed in accordance to their
guidelines.
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